[Edaily Reporter KIM JI-WAN ] Celltrion(068270)Forecasts indicate that Celltrion will continue its steep earnings growth as it expands its direct sales performance in the U.S. biosimilar market. Expectations for a revaluation of the company’s market value are rising, driven by increased sales of new products, improved profitability, and the potential to benefit from changes in U.S. healthcare coverage policies.
Celltrion’s Growth History.
Hana Securities released a report on the 18th titled “A Reliable Company Amid Market Turmoil.” In this report, the firm initiated coverage of Celltrion, assigning a “Buy” rating and a target price of 310,000 won.
Kim Seon-ah, an analyst at Hana Securities, cited the expansion of direct sales in the U.S. market and increased sales of new biosimilar products as Celltrion’s growth drivers.
Celltrion’s consolidated revenue for the third quarter of this year reached 1.5755 trillion won, a 53% increase compared to the same period last year. Operating profit rose 74% to 525.3 billion won, with an operating profit margin of 33%. Five newly launched products drove revenue growth and contributed to improved profitability.
Hana Securities estimated Celltrion’s revenue and operating profit for this year at 5.85 trillion won and 1.9 trillion won, respectively. These figures exceed the company’s annual targets of 5.3 trillion won in revenue and 1.8 trillion won in operating profit.
The outlook for next year’s performance is also bright. Hana Securities expects Celltrion’s revenue to reach 7.0699 trillion won and operating profit to reach 2.3786 trillion won in 2027.
In particular, the firm analyzed that discussions regarding the expansion of healthcare coverage in the U.S. are likely to have a positive impact on the biosimilar market. It is believed that demand for relatively affordable biosimilars could increase once discussions on expanding Medicaid coverage and policies to alleviate the burden of medical expenses begin in earnest.
Analyst Kim emphasized, “To expand welfare within a limited budget, there is no alternative but to encourage the use of biosimilars,” stressing the need for continued attention to Celltrion as it increases its market share in the U.S.
The expansion of businesses beyond biosimilars is also worth noting. Celltrion is expanding its contract manufacturing (CMO) business through the acquisition of a production facility in Branchburg, U.S. CMO revenue from Eli Lilly, which began this year, is also contributing to overall revenue growth.
Analyst Kim predicted that if increased sales of new products in the U.S. are reflected in quarterly earnings, this will serve as a key driver for the stock price to rise. In particular, he assessed that Celltrion’s business foundation will be further strengthened as both its biosimilar sales and CMO business continue to grow.
As the spread of fraud and misinformation using artificial intelligence (AI) continues to rise, investment is flowing into European startups that verify AI-generated content. The scope of investment i…
Celltrion(068270)Forecasts indicate that Celltrion will continue its steep earnings growth as it expands its direct sales performance in the U.S. biosimilar market. Expectations for a revaluation of t…
CJ ENM CO., Ltd.(035760)has filed a petition for a preliminary injunction with the court, asking it to prevent LG HelloVision(037560)from suspending broadcasts on its four channels.
(Photo: CJ ENM …